Opendata, web and dolomites

Biomode

Diagnosing Pathogen Bacteria Earlier and More Accurately with Biomode’s Probe4@ Rapid Diagnostic Kits

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Biomode" data sheet

The following table provides information about the project.

Coordinator
Biomode 2, S.A. 

Organization address
address: EDIFICIO GNRATION, PRACA CONDE AGROLONGO 123
city: BRAGA
postcode: 4700
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website https://biomode-sa.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-07-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Biomode 2, S.A. PT (BRAGA) coordinator 50˙000.00

Map

 Project objective

Over 23 million people in the Europe get ill from unsafe food every year, resulting in 5,000 deaths. The majority of foodborne diseases are diarrheal diseases including an estimated 5 million cases of campylobacteriosis annually. We have developed the Biomode Probe4@ solutions based on PNA-FISH technology. The Probe4@ products are cost-efficient, rapid and accurate molecular diagnostic tests based on Peptide Nucleic Acid Fluorescence in situ Hybridization (PNA-FISH) technology for the identification of pathogens in food safety, environmental and clinical applications. Biomode is an innovative company where the core activities are focused on R&D and the commercialization of rapid diagnostic kits based on Peptide Nucleic Acid FISH technology for microbial detection in food and clinical samples. The company focus is to develop and certify its products by internationally recognized organizations such as AOAC. Currently our products Probe4Cronobacter®, Probe4Monocytogenes® and Probe4Salmonella® have already obtained the certification mark by AOAC. In the healthcare market, our product Probe4Pylori® has recently obtained the CE mark. The EFSA has estimated that the overall economic burden of human salmonellosis could be as high as €3 billion a year. By preventing Salmonella to even to get into the retail system, early routine tests are necessary. But those will only be integrated if they are cost effective and easy to use such as the Biomode kits. Our objective is to leverage the diagnostic possibilities of PNA-FISH for all its applications in food safety, clinical and environmental fields, thereby expanding the current possibilities of molecular analysis. We are convinced that the fast, accurate, low-cost and user-friendly diagnostic of certain pathogens through Biomode’s Probe4@ will help decision makers act quickly, thereby saving lives, pain, mistakes and even preventing epidemics.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOMODE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOMODE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More  

MEDIVAC (2019)

Machine learning software to design personalized neoantigen vaccines tailored to specific vaccine delivery systems

Read More